Hua Deng

Executive Director Program Management at Stratus Therapeutics

Hua Deng has a wealth of experience in program management, clinical supply, business development, project management, and new product development. In 2023, they began working as the Executive Director Program Management at Garuda Therapeutics. From 2021-2018, they held the position of Executive Director, Program Management & Clinical Supply at Phoenix Tissue Repair, Inc. and Origin Biosciences, respectively. In 2018, they were the Sr. Director Project Management at QED Therapeutics. From 2017-2005, they held roles as Director Business Development at WuXi AppTec, Associate Director, Project Management and Sr. Project Manager at AMRI (Albany Molecular Research Inc.), Senior Manager at Colorcon Inc. Global Headquarters, Manager, Formulation Technologies at Colorcon, and Manager of New Product Development at Colorcon Inc. No-Tox Products. From 2001-2005, they were a Research Scientist at De Nora North America, Inc., (current BASF Fuel Cell division), where they developed novel manufacturing processes and commercialized new product, conducted nanocrystalline catalyst synthesis, particle engineering, powder coating and material characterization, and published two patents.

Hua Deng obtained a BS in Chemical Engineering from Zhejiang University in 1996. Hua then went on to obtain an MS in Chemical Engineering from North Carolina State University in 2002. After that, they obtained a Doctor in Chemical Engineering from Lehigh University in 2016. In 2015, they obtained a PMP certification from the Project Management Institute.

Location

Boston, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Stratus Therapeutics

4 followers

Stratus Therapeutics is redefining regenerative medicine with Stratus Prime™ — a platform for full hematopoietic system renewal, on demand. Our proprietary product, ST-101, includes both hematopoietic stem cells (Prime HSCs™) and hematopoietic progenitor cells (Prime HPCs™) to drive durable, long-term engraftment with full hematopoietic system restoration, while supporting near-term immune reconstitution.


Employees

51-200

Links